Section Arrow
CRSP.NASDAQ
- CRISPR Therapeutics AG
Quotes are at least 15-min delayed:2025/07/21 11:56 EDT
Regular Hours
Last
 66.13
+1 (+1.54%)
Day High 
71.13 
Prev. Close
65.13 
1-M High
66.49 
Volume 
4.37M 
Bid
65.99
Ask
66.13
Day Low
65.77 
Open
66.53 
1-M Low
43.2301 
Market Cap 
5.62B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 56.64 
20-SMA 52.29 
50-SMA 44.13 
52-W High 66.49 
52-W Low 30.04 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.49/-3.28
Enterprise Value
5.83B
Balance Sheet
Book Value Per Share
21.18
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
35.00M
Operating Revenue Per Share
1.97
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PMNProMIS Neurosciences1.17+0.7299+165.85%5PE
NCNANuCana plc0.052+0.0043+9.01%-- 
SABSSAB Biotherapeutics3.215+0.645+25.10%-- 
TNFATNF Pharmaceuticals Inc.0.1286+0.0411+46.97%-- 
RXRXRecursion Pharmaceuticals6.5+0.66+11.30%-- 
Quotes are at least 15-min delayed:2025/07/21 11:56 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), whichis a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.